When Should Genetic Testing Be Performed in Patients With Neuroendocrine Tumors?

Another episode in the expert opinion series. I thought this might be useful for some of you after an interesting ‘google alert’ brought up these discussions. It comprises a roundtable discussion with known NET specialists and some big hitters too.

Dr Jennifer Eads talks about the tricky issue of when Genetic Testing Be Performed in Patients with Neuroendocrine Tumors?

Jennifer R. Eads, MD

Associate Professor of Clinical Medicine
Physician Lead, GI Clinical Research
Director, National Clinical Trials Network
Director, Penn Neuroendocrine Tumor Program
Division of Hematology and Oncology
University of Pennsylvania, Abramson Cancer Center
Perelman Center for Advanced Medicine Philadelphia, PA

The discussion is centred on the following statement and question

When Should Genetic Testing Be Performed in Patients with Neuroendocrine Tumors?

Click on the blue link below to read the discussion.

Expert Perspectives | When Should Genetic Testing Be Performed in Patients With Neuroendocrine Tumors? – Expert Perspectives

This might also be useful

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.